Search results
Showing 1 to 11 of 11 results for fremanezumab
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
In development [GID-TA10992] Expected publication date: 15 May 2024
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 764.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
145,000 people in England to have further treatment choice for preventing migraine attacks.
NICE has for the first time recommended an oral treatment for preventing migraines.
NICE has begun a phased restart of publishing non-COVID-19 guidance as the NHS and wider health and care system start to return to normal arrangements.
Around 10,000 people could benefit from new migraine drug as NICE says it's cost-effective
NICE has today (12 March 2020) published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva Pharmaceuticals) for preventing chronic migraine.